About this event
Each year millions of scientific journals are published that have the potential to deliver better health outcomes. DrugBank works daily to ensure that this huge amount of data can be used to accelerate research and change lives.
As a result, we see firsthand the astonishing research taking place using our knowledge base. This webinar series is meant to highlight the amazing work done by these researchers worldwide.
Join us for a chat with professor Samuel Egieyeh as we discuss computational methods to identify existing drugs that could potentially be repurposed for COVID-19 treatment.
Together we will explore the findings from his recent paper, “Computational drug repurposing strategy predicted peptide-based drugs that can potentially inhibit the interaction of SARS-CoV-2 spike protein with its target (humanACE2).”
By analyzing molecular interactions, Egieyeh’s team was able to predict peptide-based drugs, including Sar9 Met (O2)11-Substance P and BV2, that could bind to the hACE2 receptor and inhibit the interaction with the SARS-CoV-2 spike protein. These drugs have potential applications in treating respiratory distress, viral infections, inflammation, angioedema, and enhancing antiviral agents. The findings suggest a possibility of designing new drugs based on these predictions to prevent SARS-CoV-2 infection.
Bring your questions and curiosity as we take an insiders look at this impressive research.
--
Follow along with the series to learn about new and innovative research that's powered by DrugBank.
A global provider of drug data solutions that accelerate drug research and improve healthcare delivery.